ProfileJobs

Reata Pharmaceuticals

Healthbiotechdrug developmentpharma

Reata Pharmaceuticals is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing product candidates that modulate the activity of key regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a variety of serious or life-threatening diseases.

Reata focuses on drugs with novel mechanisms of action that modulate important regulatory proteins, called transcription factors, that coordinate the cellular response to stressors by activating or suppressing the activity of many target proteins.

Revenue(FY, 2016)
$49.9 M
Market capitalization(2017-10-16)
$715.7 M
Company Growth (employees)
Type
Public
HQ
Irving, US
Founded
2002
Size (employees)
75 (est)+18%
Website
reatapharma.com
Reata Pharmaceuticals was founded in 2002 and is headquartered in Irving, US

Key People/Management at Reata Pharmaceuticals

Warren Huff

Warren Huff

President and CEO

Reata Pharmaceuticals Office Locations

Reata Pharmaceuticals has an office in Irving
Irving, US (HQ)
150 2801 Gateway Dr

Reata Pharmaceuticals Financials and Metrics

Reata Pharmaceuticals Financials

Reata Pharmaceuticals's revenue was reported to be $49.9 m in FY, 2016 which is a 1% decrease from the previous period.
USD

Revenue (FY, 2016)

49.9 m

Revenue growth (FY, 2015 - FY, 2016), %

(1%)

Net income (FY, 2016)

(6.2 m)

Market capitalization (16-Oct-2017)

715.7 m

Cash (31-Mar-2017)

82.7 m
Reata Pharmaceuticals's current market capitalization is $715.7 m.
USDFY, 2015FY, 2016

Revenue

50.3 m49.9 m

Revenue growth, %

(1%)

R&D expense

35.1 m39.5 m

General and administrative expense

13.7 m16.6 m
show all
USDFY, 2015FY, 2016

Cash

42 m84.7 m

Inventories

2.6 m

Current Assets

77.3 m87.3 m

PP&E

1.1 m819 k
USDQ2, 2016Q3, 2016Q1, 2017

Cash

92.4 m95.7 m82.7 m

Current Assets

112.9 m99.9 m85.7 m

PP&E

942 k899 k703 k

Total Assets

114.4 m101.8 m88.2 m
show all
USDFY, 2015FY, 2016

Net Income

(1.5 m)(6.2 m)

Depreciation and Amortization

1.8 m682 k

Inventories

(1.2 m)

Accounts Payable

299 k
show all
Show all financial metrics

Reata Pharmaceuticals Operating Metrics

FY, 2016

Patents Issued

240

Phase III Trials

1

Phase II Trials

4

Phase I Trials

2
Show all operating metrics

Reata Pharmaceuticals Market Value History

Market Position of Reata Pharmaceuticals

Competitors

Biogen
Health - Public
Athersys
Health - Public
Ironwood Pharmaceuticals
Health - Public
Alimera Sciences
Health - Public
Compare competitors

Traffic Overview of Reata Pharmaceuticals

Reata Pharmaceuticals Online and Social Media Presence

Reata Pharmaceuticals Company Life and Culture

You may also be interested in